Reversal of cerebral hypoperfusion: a novel therapeutic target for the treatment of AD/ADRD?

Fan Fan, Richard J. Roman

Research output: Contribution to journalComment/debatepeer-review

12 Scopus citations


Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD) are emerging global health care crises and are primarily found among aging, especially with diabetes and hypertension. However, treatments based on current understanding have not been effective. The importance of vascular contribution to AD/ADRD has been recommended by the NINDS and NIA to be a focused research area. A recent study identified that phosphatidylinositol 4,5-bisphosphate (PIP2) or its analogs could reverse cerebral hypoperfusion at the neurovascular unit in AD mice. Although more studies are needed to validate if PIP2 analogs have sustained effects on CBF and can rescue cognitive impairment in AD/ADRD, and to elucidate and clarify whether targeting the retrograde (capillary-to-arteriole) pathway is beneficial to BBB function in AD/ADRD with poor CBF autoregulation, this finding provides exciting progress in understanding vascular contributions to AD/ADRD and suggests that reversal of cerebral hypoperfusion could be a novel therapeutic target for the treatment of AD/ADRD.

Original languageEnglish (US)
Pages (from-to)1065-1067
Number of pages3
Issue number2
StatePublished - Apr 2021
Externally publishedYes

ASJC Scopus subject areas

  • Aging
  • veterinary (miscalleneous)
  • Complementary and alternative medicine
  • Geriatrics and Gerontology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Reversal of cerebral hypoperfusion: a novel therapeutic target for the treatment of AD/ADRD?'. Together they form a unique fingerprint.

Cite this